Alchemica Posted November 4, 2017 (edited) I've been hunting for a use for dihydromyricetin - stopped being interested in it after quitting drinking. Until now, I'm re-using it at the moment. Recently, The Versatile Effects of Dihydromyricetin in Health was published. The preparation of Ampelopsis as a tea is sometimes referred to as Vine tea. Traditional Chinese Medicine has utilised Ampelopsis as a medicinal herb for many centuries. The Moyeam grows in Zhangjiajie ethnic enclaves, and is considered to be the god's gift by the Tujia minority, best known as the "Tujia God tea". Dihydromyricetin (DHM) is a kind of flavonoid natural product that has been reported to display multiple pharmacological effects. Dihydromyricetin has been demonstrated to show antioxidative, anti-inflammatory, anticancer, antimicrobial, cell death-mediating, and lipid and glucose metabolism-regulatory activities. DHM exerts a more rapid antidepressant-like effect than does a typical antidepressant, in association with enhancement of BDNF expression and inhibition of neuroinflammation, being superior to venlafaxine [1]. It is traditionally used for treatment of alcohol hangovers. It has been demonstrated that dihydromyricetin may exhibit the protective effects against alcohol intoxication and alcohol tolerance. The molecular mechanism might be associated with competitively binding of dihydromyricetin to BZ sites on GABAARs [2]. DHM exerts antidiabetic effects without causing excessive body weight gain via inhibition of PPARγ phosphorylation. DHM might be a useful drug for use in type 2 diabetes insulin resistance therapy [3] Dihydromyricetin may reduce Aβ peptide production and restore gephyrin levels, GABAergic transmission, and functional synapses, leading to improvement of clinical symptoms in Alzheimer's disease. It is a potent neuroprotective agent for DA neurons by modulating the Akt/GSK-3β pathway and may be useful in Parkinson's disease [4] It is a potent natural NF-κB inhibitor and likely a useful therapeutic agent for inflammatory diseases While dihydromyricetin exhibits health-benefiting activities with minimum adverse effects, DHM has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4, CYP2E1 and CYP2D6. Further clinical studies are needed to evaluate the significance of this interaction. Edited November 4, 2017 by Alchemica 1 Share this post Link to post Share on other sites
